title: Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
abstract: This article focuses on the role of pharmacogenetics (PGx) technology across the drug development pipeline. Recent technology developments in three main areas are discussed: the discovery of polymorphisms or other variants in genes of interest; genotyping technologies used in PGx research (both for candidate gene analyses and for a whole-genome association approach); and the use of genotyping in patients prior to prescription (diagnostics). Finally, the associated issues of genetic data management and analysis are addressed, and the challenges facing the pharmaceutical industry in storing, manipulating and exploiting the large and complex data sets that will be generated from emerging PGx platforms are discussed. In conclusion, it is demonstrated that, despite the failures of some technology development programs and the slow rate of progress of others, there has, in fact, been steady progress toward the implementation of PGx within the pharmaceutical industry.
authors: AstraZeneca Pharmaceuticals, Research and Development Genetics Department, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. neil.gibson @astrazeneca.com
authors: Neil
authors: N
authors: Gibson
authors: Ansar
authors: A
authors: Jawaid
authors: Ruth
authors: R
authors: March
mesh_terms: D000818:Animals; D015195:Drug Design; D004345:Drug Industry / Q000295:instrumentation* / Q000639:trends*; D005838:Genotype; D006801:Humans; D009154:Mutation / Q000502:physiology; D010597:Pharmacogenetics / Q000295:instrumentation* / Q000639:trends*